FDA approves Pylarify for diagnosis of advanced/recurrent forms of prostate cancer

In ,a recent media release, Lantheus Holdings announced that the US Food and Drug Administration (FDA) had approved the imaging agent known as piflufolastat F 18 Injection (also known as Pylarify® or more commonly just “PyL”) as a PSMA-based PET imaging agent for identification of prostate cancer. … READ MORE …

Next-generation imaging in the management of advanced prostate cancer

A new article in the most recent issue of the Journal of Urology provides recommendations for clinicians as to the appropriate, current use of “next-generation” imaging in the treatment of advanced prostate cancer. … READ MORE …

Over- and under-imaging of newly diagnosed prostate cancer patients

This is hardly a radical new finding but yet another study has recently shown that we are over-using expensive scanning tests in the work-up of patients diagnosed with low- and intermediate-risk prostate cancer — and under-using these tests in men initially diagnosed with high-risk disease. … READ MORE …

More on PET scans and their role in prostate cancer detection

A few days ago we suggested that the role of positron emission tomography (PET scanning) as a diagnostic and prognostic tool in patients with prostate cancer was probably best limited to research studies at major medical centers at the present time. A recent study from Germany appears to confirm this suggestion. … READ MORE …

The Wednesday news reports: March 18, 2009

Today we cover reports on:

  • The incidence of prostate cancer among older HIV-positive men
  • ARTS and the potential of dutasteride in treatment of patients with biochemical recurrence
  • PET scans and their use in detection of biochemical recurrence
  • Chemotherapy in treatment of prostate cancer … READ MORE …